Cambridge: AstraZeneca and Sanofi s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of lower respiratory tract disease (LRTD) caused by.
Helsinki: Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company has announced that it has granted AstraZeneca Plc a global online STARMAP license. STARMAP is a digital AI version.
Cambridge: AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in China for the treatment of adult patients with chronic.
Cambridge: AstraZeneca s Soliris (eculizumab) has been approved in Japan for expanded use to include the treatment of generalised myasthenia gravis (gMG) in paediatric patients who are.